Cannabis reform is moving in many countries, but not in one direction or at one speed. Medical access, decriminalisation and adult-use regulation are distinct policies, even when headlines group them together. The useful global story is therefore not that the world is simply liberalising. It is that governments are testing different answers to different problems.
Europe: implementation after reform
Germany's changes have made it the continent's most closely watched case, while other European governments continue to debate narrower medical programmes or broader reform. The test is no longer legislation alone. It is whether doctors can prescribe, patients can afford treatment and regulators can maintain quality as demand changes.
For the UK, European comparisons expose how much depends on health-system design. A legal category without reimbursement, training and referral routes produces a very different result from one integrated into routine care.
North America: states and federal law
The United States remains a patchwork. State markets and medical programmes have expanded while federal scheduling and banking questions continue to shape research and commerce.
This split makes national headlines easy to overread. A federal procedural step may matter greatly without immediately changing what a patient or business can do in a particular state.
Latin America: access on paper and in practice
Countries including Colombia, Uruguay, Argentina and Brazil have developed different forms of medical or regulated access. Their experience underlines a recurring lesson: authorisation does not guarantee affordability, domestic supply or a simple route for patients.
The pattern beneath the headlines
Across regions, reform is shifting from the question of whether cannabis should be permitted to the more demanding question of how it should be governed. The countries worth watching are not only those announcing change, but those publishing outcomes, correcting failures and building systems that patients can actually use.
Momentum is real. Convergence is not. Any global roundup that ignores those differences risks turning complicated policy experiments into a victory lap.
